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The NAD+-dependent protein deacetylase SIRT6
regulates genome stability, cancer, and lifespan.
Mice overexpressing SIRT6 (MOSES) have lower
low-density lipoprotein cholesterol levels and are
protected against the physiological damage of
obesity. Here, we examined the role of SIRT6 in
cholesterol regulation via the lipogenic transcription
factors SREBP1 and SREBP2, and AMP-activated
protein kinase (AMPK). We show that SIRT6 re-
presses SREBP1 and SREBP2 by at least three
mechanisms. First, SIRT6 represses the transcription
levels of SREBP1/SREBP2 and that of their target
genes. Second, SIRT6 inhibits the cleavage of
SREBP1/SREBP2 into their active forms. Third,
SIRT6 activates AMPK by increasing the AMP/ATP
ratio, which promotes phosphorylation and inhibition
of SREBP1 by AMPK. Reciprocally, the expression of
miR33a and miR33b from the introns of SREBP2 and
SREBP1, respectively, represses SIRT6 levels.
Together, these findings explain the mechanism
underlying the improved cholesterol homeostasis in
MOSES mice, revealing a relationship between fat
metabolism and longevity.INTRODUCTION
Sirtuins are homologs of the yeast NAD+-dependent SIR2 de-
acetylase, which was shown to regulate yeast lifespan. The
sevenmammalian sirtuins, SIRT1–7, were implicated in the regu-
lation of various aging-related pathways such as cellular senes-
cence, inflammation, and genome stability. However, to date,
only SIRT6 was shown to directly regulate mammalian lifespan
(Kanfi et al., 2012).
SIRT6 possesses histone H3 K9 and K56 deacetylase activity
(Michishita et al., 2008, 2009; Yang et al., 2009). On chromatin,
SIRT6 functions to attenuate NF-kB signaling by deacetylating
H3K9 on NF-kB target gene promoters (Kawahara et al., 2009).
Similarly, SIRT6 also represses HIF-1a-regulated genes by de-
acetylating their promoters (Zhong et al., 2010). As a result,
SIRT6 depletion enhances glycolysis due to an increase in theCelexpression levels of glycolytic genes. Many cancer cells produce
energy by increasing aerobic glycolysis instead of oxidative
metabolism, a phenomenon known as the ‘‘Warburg effect’’
(Warburg, 1956). Thus, SIRT6 also functions as a tumor suppres-
sor that regulates aerobic glycolysis in cancer cells (Sebastia´n
et al., 2012). Interestingly, SIRT6 regulates other cancer-related
pathways, including genome stability, by modulating DNA dou-
ble-strand break repair, base excision repair (BER), and telomere
maintenance (Kawahara et al., 2009; Mostoslavsky et al., 2006).
Mice genetically deficient in SIRT6 display a set of premature-
aging-like phenotypes, such as lymphopenia, loss of subcutane-
ous fat, and lordokyphosis and die at about 4 weeks of age
(Mostoslavsky et al., 2006). The mice also exhibit hypoglycemia
as a result of a significant increase in glucose uptake due to
higher expression levels of the glucose transporter, GLUT1. Pre-
vious results have shown SIRT6 to be involved in the dietary re-
striction response that is known to extend mouse lifespan (Kanfi
et al., 2008). In addition, when fed a high-fat diet (HFD), trans-
genic mice overexpressing SIRT6 (MOSES), in comparison to
their wild-type (WT) littermates, accumulate significantly less
visceral fat, low-density lipoprotein (LDL) cholesterol, and tri-
glycerides (Kanfi et al., 2010). The effect of SIRT6 on cholesterol
levels is not limited toHFD. In comparison to theirWT littermates,
MOSES mice have significantly lower cholesterol levels even
when fed a regular chow diet. Thus, the mechanism underlying
the regulation of cholesterol homeostasis by SIRT6 may shed
further light on its metabolic effects.
Sterol regulatory element binding proteins (SREBPs) are lipo-
genic transcription factors that are regulated by cholesterol, in-
sulin, and glucose (Horton et al., 2002). The mammalian genome
contains two distinct SREBP genes: SREBP1 and SREBP2.
SREBP1 mainly regulates lipogenic processes by activating
genes involved in fatty acid and triglyceride biosynthesis,
whereas SREBP2 mostly activates genes involved in cholesterol
synthesis. The SREBP1 gene produces two different isoforms,
which differ in their first exon, SREBP1a and SREBP1c, owing
to the use of different transcription start sites on the SREBP1
gene (Miserez et al., 1997). SREBPs become active upon proteo-
lytic processing of the inactivate precursor in the endoplasmic
reticulum (ER), which releases a transcriptionally active N-termi-
nal basic helix-loop-helix (bHLH) zip domain. A complex
comprising S1P and S2P proteases and SCAP cleaves SREBPs
into their active forms. The mature form translocates to the
nucleus and promotes a lipogenic program in the liver. SREBP
activates itself and its target genes by binding to sterol regulatoryl Reports 4, 905–912, September 12, 2013 ª2013 The Authors 905
Figure 1. SIRT6 Overexpression Reduces Cholesterol and Triglyc-
eride Levels and Expression of Lipogenic Genes in Hepatocytes
Cholesterol (left panel) or triglyceride (right panel) levels in (A) HepG2 cells
transfected with SIRT6 or empty vector, and in (B) HepG2 cells transfected
with control siRNA (si-control) or siRNA against SIRT6 (si-SIRT6). Represen-
tative western blots demonstrating SIRT6 levels are shown on the right.
Expression profile (qRT-PCR) of fatty acid and triglyceride biosynthesis genes
in (C) HepG2 cells overexpressing SIRT6, relative to cells transfected with
906 Cell Reports 4, 905–912, September 12, 2013 ª2013 The Authorelements (SREs) located at the various promoters. Therefore,
dysregulation of SREBPs was shown to be involved in type-2
diabetes, dyslipidemia, and hepatic steatosis (Raghow et al.,
2008).
The heterotrimeric serine/threonine kinase, AMPK (AMP-
activated protein kinase), is one of the major energy sensors in
eukaryotic cells (Kahn et al., 2005). AMPK is ubiquitously
expressed and functions as an intracellular fuel sensor, thereby
maintaining energy balance. AMPK is highly sensitive to changes
in AMP levels. Therefore, a slight increase in the AMP/ATP ratio
results in AMPK’s activation via the phosphorylation of Thr172 by
its kinases, LKB and CaMKK (Corton et al., 1994; Hardie et al.,
1999). Recently, it was shown that the ADP/ATP ratio also con-
tributes to the regulation of AMPK (Oakhill et al., 2011). Once
activated, AMPK phosphorylates a wide variety of downstream
targets, resulting in the overall outcome of activating ATP-pro-
ducing processes, while extinguishing ATP-consuming ones
(Merrill et al., 1997). The net activation of AMPK results in hepatic
fatty acid oxidation, and the inhibition of cholesterol and triglyc-
eride synthesis, and lipogenesis. SREBP1 activity was recently
shown to be negatively regulated by AMPK. Phosphorylation of
SREBP1 on Ser372 by AMPK inactivates SREBP1 by suppress-
ing its cleavage and nuclear translocation and attenuates hepat-
ic steatosis and atherosclerosis in mice (Li et al., 2011).
In this study, we examine the role of SIRT6 in cholesterol regu-
lation via SREBP1/SREBP2 and AMPK. We show that SIRT6
represses SREBP1 and SREBP2 on at least three levels. First,
SIRT6 represses the transcription of SREBP1 and SREBP2
and their target genes. Second, SIRT6 inhibits the cleavage of
SREBP1 and SREBP2 into their active forms. Finally, SIRT6
activates AMPK by increasing the AMP/ATP ratio, promoting
the phosphorylation and inhibition of SREBP1. Together, these
findings explain themechanism underlying the improved choles-
terol homeostasis in MOSES mice, revealing a connection
between energy homeostasis and longevity.
RESULTS
Previously, we showed that mice overexpressing SIRT6 have
lower LDL cholesterol levels in comparison to their WT litter-
mates (Kanfi et al., 2010). To examine if this effect is systemic
or cell autonomous, we followed the levels of cholesterol and tri-
glycerides in hepatoma HepG2 cells transfected with an empty
vector or a SIRT6 expression plasmid. As seen in Figure 1A,
cholesterol (left panel) and triglyceride (right panel) levels were
significantly lower in cells overexpressing SIRT6. Conversely,
knockdown of SIRT6 by small interfering RNA (siRNA) resulted
in a significant increase in cholesterol (left panel) and triglyceride
(right panel) levels (Figure 1B). To further examine the role of
SIRT6 in regulating fat homeostasis, the expression levels ofempty vector (WT), and in (D) HepG2 cells knocked down for SIRT6, relative to
cells with si-control (WT). A ChIP experiment followed by qRT-PCRmeasuring
(E) SIRT6 binding or (F) histone H3K56Ac levels at the promoter regions of
SREBP1, SREBP2, and their target genes, in HepG2 cells overexpressing
empty vector (WT) or SIRT6. An anti-H3 Abwas used as a positive control (data
not shown); anti-GFP was used as a negative control (N.C.).
Data represent means ± SEM, *p% 0.05. See also Figure S1.
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Figure 2. Effect of SIRT6Overexpression on
Lipogenic Gene Transcription Mediated by
AMPK
(A) Representative western blot analysis of
SREBP1/SREBP2, AMPK, p-AMPK (Thr172),
ACC, p-ACC (Ser 79) and SIRT6 in HepG2 cells
overexpressing SIRT6 or empty vector. P and N
designate the precursor (125 kDa) and nuclear
(65 kDa) forms, respectively, of SREBP1/2.
Densitometric quantification of p-AMPK, p-ACC,
and pSREBP1 from three different blots is shown
below.
(B) qRT-PCR analysis of SCAP, S1P, and S2P
under SIRT6 overexpression (gray bars), relative to
vector alone (black bars).
(C) ChIP experiment followed by qRT-PCR
measuring SIRT6 binding at the promoter regions
of SCAP, S1P, and S2P in HepG2 cells over-
expressing empty vector (black bars) or SIRT6
(gray bars).
(D) Western blot analysis of S1P, S2P, and SCAP
in HepG2 cells overexpressing empty vector or
SIRT6.
(E) AMP/ATP ratio in HepG2 cells transfected with
SIRT6 or empty vector. Results shown are the
means ± SEM from five independent measure-
ments and were normalized to 1 for the control
cells.
(F) Western blot analysis of pLKB, LKB, and
CaMKKb in HepG2 cells overexpressing empty
vector or SIRT6.
(G) Expression levels of SREBP1/SREBP2 target
genes in HepG2 cells transfected with SIRT6
togetherwith scrambledRNA (graybars) or siAMPK
(dark gray bars), relative to vector alone (black
bars). The efficacy of the siRNA is shown above. In
all blots, b-actin served as a loading control.
Data represent means ± SEM, *p % 0.05, **p %
0.01. See also Figures S2 and S3.genes involved in fatty acid and triglyceride biosynthesis were
examined in WT and SIRT6-overexpressing HepG2 cells. Quan-
titative real-time PCR (qRT-PCR) of the mRNA levels of SREBP1
and SREBP2 and their target genes FASN, ACC1, ACC2, LDLR,
HMGCR, HMGCS, and SCD1 showed that they were signifi-
cantly lower under conditions of SIRT6 overexpression (Fig-
ure 1C). Reciprocally, knockdown of SIRT6 by siRNA resulted
in a significant increase in the mRNA levels of these genes (Fig-
ure 1D). Similarly, in comparison to the WT liver, the expression
levels of selected SREBP1 and SREBP2 target genes, including
FASN, ACC1, ACC2, LDLR, HMGCR, and HMGCS, were signif-
icantly lower in the liver of SIRT6 transgenic mice (Figure S1).Cell Reports 4, 905–912, SeSIRT6 negatively regulates the tran-
scription of its target genes by binding
and deacetylating its promoter on histone
H3 K9 and K56. Indeed, chromatin immu-
noprecipitation (ChIP) demonstrated that
SIRT6 binds to the promoter region of
SREBP1c, SREBP2, SCD1, and HMGCS
(Figure 1E). Moreover, ChIP analysis
showed that, in comparison to WT cells,the levels of H3K56Ac on these promoters was significantly
lower in SIRT6-overexpressing cells (Figure 1F). Thus, these re-
sults suggest that SIRT6 represses the transcription of these
genes by deacetylating histone H3 K56 on these promoters.
Additional layers of regulation control SREBP1 and SREBP2
activity. First, posttranslational cleavage of SREBP1 and
SREBP2 liberates a transcriptionally active fragment of these
proteins, which translocates to the nucleus (Brown and Gold-
stein, 1997). In addition, SREBP1 is negatively regulated upon
phosphorylation by AMPK. Therefore, we determined whether
SIRT6 affects these modes of SREBP1/SREBP2 regulation. As
seen in Figure 2A, overexpression of SIRT6 in HepG2 cellsptember 12, 2013 ª2013 The Authors 907
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Figure 3. Reciprocal Regulation between
SIRT6 and miR-33
(A) Target sequence for miR-33a and miR-33b in
SIRT6 30 UTR.
(B and C) SIRT6 (B) and SREBP1/SREBP2 (C)
protein levels following overexpression or down-
regulation of miR-33a. b-actin bands served as a
loading control. SC, scrambled sequence.
(D) qRT-PCR expression profile of miR-33a and
miR-33b in HepG2 cells overexpressing SIRT6.
(E) qRT-PCR analysis of miR-33 expression in liver
fromWT and SIRT6 transgenic (TG) male mice (n =
8 per group). R.I., relative intensity.
Data represent the mean ± SEM. *p% 0.05.blocked the cleavage of SREBP1 and SREBP2, reducing the for-
mation of the nuclear active forms. In addition, SIRT6 overex-
pression resulted in a significant reduction in the transcript levels
of SCAP, S1P, and S2P, three members of the protein complex
that cleaves SREBP1 and SREBP2 (Figure 2B). In support of this
notion, ChIP analysis demonstrated that SIRT6 bound to the pro-
moter region of SCAP, S1P, and S2P (Figure 2C). Similarly,
SIRT6 overexpression resulted in a decrease in SCAP, S1P,
and S2P protein levels (Figure 2D). Thus, SIRT6 overexpression
blocks the processing and activity of SREBP1 and SREBP2.
To further elucidate AMPK’s regulation of SREBP, the levels of
phosphorylated Ser372 of SREBP1c, a known AMPK inhibition
target, were examined. As seen in Figure 2A, SREBP1c phos-
phorylation was significantly elevated in cells overexpressing
SIRT6. The increase in phosphorylated SREBP1c under SIRT6
overexpression prompted us to follow the levels of AMPK activity
in HepG2 cells overexpressing SIRT6 versus an empty vector. In
agreement with the increase in phosphorylated SREBP1c, SIRT6
overexpression resulted in a significant increase in phosphory-
lated AMPK (Thr172) and in its phosphorylated substrate,
p-ACC (Figure 2A). qRT-PCR demonstrated that SIRT6 overex-
pression in vivo results in a significant increase in the transcrip-
tion levels of AMPK in the liver (Figure S2). An increased level of
AMPK is known to promote fatty acid beta oxidation (Viollet
et al., 2009). Indeed, the levels of liver HADHB, CPT, and
CROT, rate-limiting enzymes in oxidation of beta free fatty acids,
were significantly increased in parallel to AMPK (Figure S2).
An increased AMP/ATP ratio activates AMPK. Indeed, in com-
parison to control cells, the AMP/ATP ratio was 2-fold higher in
SIRT6-overexpressing cells (Figure 2E). AMPK is considered
ultrasensitive to ATP depletion and, consequently, to AMP eleva-
tion. Therefore, the observed 2-fold increase in AMP/ATP ratio is
sufficient to activate AMPK (Hardie and Hawley, 2001). Similarly,908 Cell Reports 4, 905–912, September 12, 2013 ª2013 The AuthorsSIRT6 overexpression also resulted in an
increase in ADP/ATP ratio, which can
also activate AMPK (Figure S3) (Oakhill
et al., 2011). Activation of LKB (Shaw
et al., 2005; Woods et al., 2003) or
increased levels of CaMKKb (Hawley
et al., 2005; Woods et al., 2005) were
shown to activate AMPK, as well. As
seen in Figure 2F, SIRT6 overexpression
resulted in an increase in the active formof LKB (pLKB Ser428) and no change in CaMKKb levels.
Together, these findings suggest that the reduction in the
expression of lipogenic gene transcription due to SIRT6 overex-
pression is mediated, at least partially, via AMPK.
To examine this possibility, we followed the effect of SIRT6
overexpression on the levels of lipogenic genes in the presence
or absence of AMPK. SIRT6 overexpression significantly
reduced the RNA levels of FASN, ACC1, ACC2, LDLR, HMGCR,
HMGCS, SCD1, and SREBP1c in HepG2 cells. However, reduc-
tion in AMPK expression by siRNA, which targets both AMPK
isoforms, restored the RNA levels of these genes (Figure 2G).
Thus, the inhibitory effect of SIRT6 on expression of these genes
is mediated by AMPK. Together, these findings reveal additional
mechanisms by which SIRT6 inhibits the expression of lipogenic
genes. SIRT6 suppresses transcriptional activation cleavage of
SREBP1 and SREBP2 by reducing levels of SCAP, S1P, and
S2P. In addition, by increasing the AMP/ATP ratio and stimu-
lating AMPK phosphorylation, SIRT6 inhibits SREBP1c.
MiR-33a andmiR-33b are transcribed from introns of SREBP2
and SREBP1, respectively, and were shown to regulate SIRT6
levels (Figure 3A) (Da´valos et al., 2011). We therefore examined
the possibility of a feedback regulation of SIRT6 by SREBP1/
SREBP2 via miR-33a and miR-33b. Given that the seed se-
quences of both miR’s are identical, we followed the effect of
only miR-33a. HepG2 cells were transfected with miR-33a or
with a scrambled control miR. As seen in Figure 3B, miR-33a
overexpression resulted in a 30% reduction in SIRT6 protein
levels. Conversely, transfection with antagomir against miR-
33a resulted in a 30% increase in SIRT6protein levels (Figure 3B).
Moreover, miR-33a also affected levels of SREBP1/2, targets of
SIRT6 (Figure 3C). These findings show that SIRT6 is a target for
miR-33a and suggests a negative-feedback regulation between
SIRT6 and SREBP1/SREBP2. Indeed, qRT-PCR showed that
Figure 4. Effect of SIRT6 Overexpression on SREBP and AMPK
Activities in Old Mice
(A) Western blot analysis of pAMPK, AMPK, SREBP1, and SIRT6 in 24-month-
old WT and MOSES (TG) mice. b-actin served as a loading control. Densito-
metric quantification of p-AMPK/AMPK is shown on the right. (n = 4 mice per
group).
(B) Expression profile (qRT-PCR) of fatty acid and triglyceride biosynthesis
genes in the liver of 24-month-oldWT andMOSESmice (n = 4mice per group).
Data represent the mean ± SEM. *p% 0.05.
(C) Model of the reciprocal regulation between SIRT6 and SREBP1 and
SREBP2. Upon expression of SREBP1 and SREBP2, miR-33 is cotranscribed,
resulting in the downregulation of SIRT6. On the other hand, SIRT6 activates
AMPK (by increasing the AMP/ATP ratio and activating LKB), which phos-
phorylates and inactivates SREBP1. SIRT6 also binds and deacetylates
H3K56 of SREBP1 and SREBP2 promoter regions, potentially making these
sites inaccessible for transcription. Moreover, SIRT6 decreases the levels of
the SREBP1/SREBP2 protease complex (SCAP, S1P, and S2P), which results
in diminished levels of the active forms of SREBP1 and SREBP2.
See also Figure S4.
Celoverexpression of SIRT6 in HepG2 cells resulted in a 30%
decrease in miR-33a and miR-33b levels (Figure 3D). Similarly,
a 40% decrease in miR-33a (the single isoform in mice) expres-
sion was detected in the liver of SIRT6-overexpressing trans-
genic male mice (Figure 3E).
In mice, SIRT6 overexpression protects against the physiolog-
ical damage induced by HFD and extends lifespan. Thus, we
examined SIRT6 regulation of AMPK and SREBP in mice fed
HFD and in old mice. No significant change was found in pAMPK
and cleaved SREBP1 in the liver between WT and MOSES mice
fed HFD (Figure S4A). However, in comparison to WT liver, the
expression levels of selected SREBP1 and SREBP2 target
genes, including FASN, ACC1, ACC2, LDLR, HMGCR, and
HMGCS, were significantly lower in the liver of SIRT6 transgenic
mice (Figure S4B). Interestingly, in 24-month-old mice, in com-
parison to WT, MOSES mice had increased liver pAMPK and a
significant reduction in the expression levels of the selected
SREBP1 and SREBP2 target genes (Figures 4A and 4B). Thus,
SIRT6 maintains part of its regulation of SREBP in aged mice
and in mice fed HFD.
DISCUSSION
Mice overexpressing SIRT6 have lower cholesterol levels in
comparison to their WT littermates. To further investigate the
molecular basis for this phenomenon, we found that both
HepG2 hepatoma cell cultures and liver tissues of SIRT6-over-
expressing mice exhibit a significant decrease in triglyceride
and cholesterol levels, indicating that these are most likely cell
autonomous phenomena. In search of molecular mechanisms
underlying these phenomena, we demonstrated that SIRT6
overexpression significantly reduces the levels of SREBP1 and
SREBP2 and their target genes, as well as the level of the active
cleaved forms of SREBP1 and 2. In parallel, SIRT6 overexpres-
sion results in increased levels of inactive phosphorylated
SREBP1, AMP/ATP ratio, and LKB and AMPK activation. Finally,
miR-33a and miR-33b, which are hosted within SREBP2 and
SREBP1, respectively, bind to the SIRT6 transcript and reduce
SIRT6 expression. Together, these findings demonstrate a recip-
rocal regulatory relationship between SIRT6 and SREBP1/
SREBP2 and indicate that SIRT6 is a key regulator of cholesterol
homeostasis and an AMPK activator (Figure 4C).
In support of this notion, we found that overexpression of
SIRT6 results in at least three levels of negative regulation
of SREBP1 and SREBP2: a reduction in the transcription levels
of SREBP1 and SREBP2, a reduction in the active nuclear
cleaved forms of SREBP1 and SREBP2 and an increase in the
level of the inactive phosphorylated form of SREBP1. However,
the hierarchy between the above regulatory pathways is still
not clear. SREBP1 and SREBP2 are known to regulate their
own transcription. Therefore, it is possible that the reduction in
the transcription levels of SREBP1 and SREBP2 is the outcome
of significantly reduced levels of active SREBP1/SREBP2 pro-
tein, potentially due to SIRT6-dependent AMPK activation.
SIRT6/AMPK reduces SREBPs activity to a level that signifi-
cantly affects their target genes (p < 0.05), whereas its effect
on SREBP1c itself was almost significant (24% reduction and
p = 0.061) (Figure 2G). Thus, we suggest that SIRT6’s directl Reports 4, 905–912, September 12, 2013 ª2013 The Authors 909
effect on SREBP mRNA levels and SREBPs autoregulation are
masked by the activity of other genes. Nevertheless, the binding
of SIRT6 to SREBP1/SREBP2 promoters strongly suggests that
part of the reduction is due to the deacetylation of SREBP1/
SREBP2 promoter regions by SIRT6. Indeed, a significant
decrease in the acetylation levels of histone H3 K56 but not K9
was found on these promoters in SIRT6-overexpressing cells
versus WT (Figure 1F; data not shown). Thus, SIRT6 binding to
SREBP1/SREBP2 promoters reduce their transcription levels
specifically via H3 K56 deacetylation.
Overexpression of SIRT6 results in significantly increased
levels of liver rate-limiting enzymes in the oxidation of beta free
fatty acids, HADHB, CPT1, and CROT. In addition, ACC2 levels
significantly decreased. At the mitochondrial membrane, ACC2
activity results in increased malonyl-coA levels, which inhibits
carnitine/palmitoyl-transferase 1 (CPT1) and reduces fatty acid
b-oxidation (Abu-Elheiga et al., 2001). All together, these obser-
vations suggest an appealing model in which SIRT6 overexpres-
sion also enhances fatty acid b-oxidation.
Our finding that SIRT6 activates AMPK suggests that addi-
tional SIRT6-related phenotypes may also be mediated by
AMPK activation. Of the many reported AMPK-regulated path-
ways, we wish to highlight glucose homeostasis, cancer, and
aging. Regarding glucose homeostasis, mice overexpressing
SIRT6 were shown to be protected from an obesity-related
decline in glucose uptake, usually associated with obesity-
related type 2 diabetes (T2D) (Kanfi et al., 2010). Similarly, in
comparison to their WT littermates, SIRT6-overexpressing old
mice (19–24 months) are protected against an age-related
decline in glucose uptake (Kanfi et al., 2012), which is also asso-
ciated with obesity-related T2D. Interestingly, metformin, an
AMPK activator, is, to date, the most highly prescribed medicine
used for the treatment of T2D. Thus, it would be of great interest
to determine whether the protective effect of SIRT6 against T2D
is partially mediated by AMPK.
In a recent study, Sebastia´n et al. (2012) demonstrated the role
of SIRT6 as a tumor suppressor that modulates aerobic glycol-
ysis and inhibits the Warburg effect. Similarly, Faubert et al.
(2013) showed that AMPK is a negative regulator of the Warburg
effect and acts as a tumor suppressor. Inactivation of AMPK in
both transformed and nontransformed cells promotes a meta-
bolic shift to aerobic glycolysis and biomass accumulation.
Given this parallel together with the fact that both SIRT6 and
AMPK act as tumor suppressors via hypoxia-inducible factor-
1a (HIF-1a), it would be of great interest to examine whether
the tumor-suppressive role of SIRT6 is mediated by AMPK.
To date, SIRT6 is the only sirtuin that has been shown to
directly regulate mammalian lifespan. The expression levels of
SIRT6 have been shown to increase in multiple tissues of rats
fed with a calorie restricted diet, an energy-limited condition
known to extend the rat lifespan (Kanfi et al., 2008). Moreover,
maleMOSESmice overexpressing SIRT6 live significantly longer
than their WT littermates (Kanfi et al., 2012). Strikingly, AMPK is
also activated under energy-limited conditions and, in the nem-
atode C. elegans, AMPK activation results in long-living animals
regardless of their diet (Apfeld et al., 2004). A recent study by
Stenesen et al. (2013) showed that various mutations in AMP
biosynthesis, which tip the balance toward an increase in the910 Cell Reports 4, 905–912, September 12, 2013 ª2013 The AuthorAMP/ATP ratio, result in a significant AMPK-dependent increase
in the lifespan of the fruit fly, D. melanogaster. Interestingly, we
found that SIRT6 maintains part of its regulation on SREBP
and AMPK in aged mice (Figures 4A and 4B). We therefore sug-
gest that SIRT6/AMPK reduces SREBPs activity to a level that
strongly affects SREBPs target genes, whereas its effect on
SREBPs mRNA levels is masked by other regulators of SREBPs.
Although the precise role of AMPK in mammalian longevity is still
elusive, it would be of great interest to examine the extent to
which the positive effect of SIRT6 on mammalian lifespan is
mediated by AMPK.
All together, these findings demonstrate the key role of SIRT6
as a regulator of the connection between energy homeostasis
and longevity. Therefore, small molecules that can activate
SIRT6may have potential as drugs for treating age-relatedmeta-
bolic diseases, such as hypercholesterolemia, increased LDL




Mice were kept under specific pathogen-free conditions, were raised under
12 hr day/night conditions, and had free access to standard chow diet and wa-
ter. All experimentswere conducted in accordancewith the Institutional Animal
Care andUseCommittee. The Sirt6-tg/MOSESonCB6backgroundmicewere
described previously (Kanfi et al., 2010). For mouse experiments, 6-month-old
male mice (WT and SIRT6 transgenic) were sacrificed, and RNA was purified
from livers and processed as described in the section ‘‘Gene Expression Anal-
ysis’’ below. Aged mice were sacrificed at the age of 24 months. Mice used for
HFD experiments were fed a diet with 60% of calories from fat for 16 weeks
as previously described (Kanfi et al., 2010). Eight backcrosses were done with
WT CB6 before the beginning of the HFD experiments.
Cell Culture and Reagents
The HepG2 human hepatocarcinoma cell line was grown in complete Dulbec-
co’s modified Eagle’s medium (low glucose) medium supplemented with 10%
fetal calf serum, 1% penicillin-streptomycin mixture, and L-glutamine. For
transfection, cells were grown to 50% confluency in 6-well or 10 cm plates.
Transfection was performed using the lipofectamine (Invitrogen) method.
The cells were harvested 48 hr after transfection. For SIRT6 transfections,
2 mg DNA (6-well plate) or 10 mg DNA (10 cm plate) was used. For siRNA trans-
fections, cells were transfected with siRNAs (IDT) at a concentration of 50 nM,
using DharmaFECT1 (Dharmacon), and harvested as indicated. MiR-33a and
antimiR-33a were purchased from Applied Biosystems by Life Technologies
and transfected using siPORT NeoFX transfection reagent.
Lysate Preparation and Immunoblotting
Cells were lysed in lysis buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol,
1% Triton X-100, 1 mM EDTA, 1 mM EGTA, and protease inhibitor cocktail).
Cleared lysates were resolved by SDS-PAGE, transferred to nitrocellulose,
and incubated with primary antibodies. Immunoreactive bands were detected
using ECL reagents (Pierce). For immunoblot analysis of SIRT6, monoclonal
anti-SIRT6 was used (Sigma). Anti b-actin was purchased from Santa Cruz
Biotechnology. Anti-SREBP1 and SREBP2 were purchased fromBD Pharmin-
gen. Anti-AMPK, p-AMPK (Thr172), ACC, p-ACC (Ser79), LKB, p-LKB
(Ser428), S2P, and pSREBP1 (Ser372) were purchased from Cell Signaling
Technology. S1P and SCAP antibodies were purchased from Abcam. The
CaMKKb antibody was purchased from Bethyl Laboratories and the H3K56
antibody was purchased from Epigentek.
Gene Expression Analysis
RNA was extracted from cells with Peqgold Trifast (PEQLAB Biotechnologie)
according to the manufacturer’s specifications. Afterward, from each sample,s
2.5 mgwas taken to a standard reverse transcription (first-strand cDNA synthe-
sis kit, MBI Fermentas). The qRT-PCR was carried out using SYBR green
fluorescent dye (Thermo Fisher Scientific), in a 15 ml total reaction volume con-
taining 3 ml of cDNA. PCR amplification was performed with a StepOnePlus in-
strument (Applied Biosystems). A list of PCR primers is available on request.
High-Performance Liquid Chromatography Nucleotide Analysis
Sample preparation method for high-performance liquid chromatography
(HPLC) analysis was adapted from the procedure of Manfredi and colleagues
(Manfredi et al., 2002). Briefly, cells were suspended in 400 ml of cold 0.4 M
perchloric acid in 1.5 ml Eppendorf tubes. The mixture was incubated on ice
for 15 min, centrifuged at 12,000 3 g to remove the precipitate. The superna-
tant was neutralized (approximately 1:10) with 4MK2CO3 solution (pH 7.5), fol-
lowed by incubation for 15 min on ice. Following centrifugation (10,000 3 g),
the supernatants were frozen pending chromatographic analysis. The chroma-
tography apparatus consisted of Hitachi Elite LaChrom system equipped with
diode array detector, column oven, autosampler, and a quaternary pump. All
chromatographic analyses were performed at 30C using SUPELCOSIL LC-
18-S HPLC Column (5 mm particle size, L 3 I.D. 25 cm 3 2.1 mm), flow rate
of 0.2 ml/min under isocratic elution conditions with the following buffer
composition: 50 mM potassium phosphate, 100 mM triethylamine, 0.1 mM
MgCl2 (pH 6.5) (adjusted with phosphoric acid)]:Acetonitrile (98.5:1.5). Each
analysis cycle was set to 30 min. The chromatographic flow was monitored
at 260 nm and integrated using EZChrom Elite Software (Cichna et al., 2003;
Czarnecka et al., 2005; Kehr and Chavko, 1985).
Cholesterol Measurements
Cells were harvested by scraping, and extracted with 200 ml of chloroform:iso-
propanol:NP-40 (7:11:0.1) in a microhomogenizer. The extracts were centri-
fuged at 15,000 3 g for 10 min. The liquid organic phase was transferred to
a new tube and air-dried at 50C to remove chloroform. Afterward the samples
were put under vacuum for 30 min to remove trace organic solvent. The
extracts were further analyzed using an assay kit, according to the manufac-
turer’s instructions (Cayman Chemical, cholesterol fluorometric assay kit).
Triglyceride Measurements
Cells were harvested by scraping and were homogenized in a 1 ml solution
containing 5% NP-40 in water while slowly heating to 100C. The samples
were then cooled to room temperature and heated again to 100C to ensure
solubilization of all triglycerides. The samples were centrifuged for 2 min to
remove any insoluble material and analyzed using an assay kit, according to
the manufacturer’s instructions (Cayman Chemical, triglycerides colorimetric
assay kit).
Chromatin Immunoprecipitation
Experiments were performed as previously described (Kanfi et al., 2010).
Briefly, formaldehyde was added directly to cell cultures, to a final concentra-
tion of 1%. Fixation proceeded at 37C for 10 min, and afterward cells were
harvested by scraping in ice-cold PBS containing protease inhibitor. The cell
pellets were resuspended in lysis buffer and then sonicated to shear DNA to
segments of 500–1000 bp. After centrifugation, the chromatin solution was
precleared with the addition of protein A/G agarose beads for 45 min at 4C.
Thereafter, each sample was incubated with the indicated antibody overnight
at 4C (an anti-H3 antibody was used as a positive control, and an anti-GFP
antibody was used as a negative control), washed with several wash buffers
to reduce background, and then eluted with NaHCO3 (50 mM). Crosslinks
were reversed by addition of NaCl to a final concentration of 200 mM. Next,
20 ml proteinase K solution, 50 mM Tris (pH 7.5), and 10 mM EDTAwere added
to a total elution volume of 500 ml. DNA samples were purified by a PCR clean
up kit (Promega). Each gene was checked up to 2,000 bp upstream of its tran-
scription start site, in segments of 700 bp, each tested separately with a
distinct set of primers in qRT-PCR. Table S1 shows the sequences of the
primers that were used for the ChIP analysis.
Gel Quantification Analysis
Quantification of bands was performed using the ImageJ 1.42 densitometry
software.CelStatistical Analyses
Significant differences between two groups were assessed by two-tailed
Mann-Whitney test. Data are expressed as means ± SEM. Values of p <
0.05 were considered to be statistically significant. All experiments were per-
formed at least three times.SUPPLEMENTAL INFORMATION
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